scholarly journals DNAM-1 Mediates Epithelial Cell-Specific Cytotoxicity of Aberrant Intraepithelial Lymphocyte Lines from Refractory Celiac Disease Type II Patients

2011 ◽  
Vol 186 (11) ◽  
pp. 6304-6312 ◽  
Author(s):  
Jennifer M.-L. Tjon ◽  
Yvonne M. C. Kooy-Winkelaar ◽  
Greetje J. Tack ◽  
A. Mieke Mommaas ◽  
Marco W. J. Schreurs ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Epithelial Cell ◽  
Disease Type ◽  
Intraepithelial Lymphocyte ◽  
Type Ii ◽  
Refractory Celiac Disease ◽  
Specific Cytotoxicity

Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer

2016 ◽  
Vol 25 (3) ◽  
pp. 385-388 ◽  
Author(s):  
Yvette H. Van Beurden ◽  
Tom Van Gils ◽  
Nienke A. Van Gils ◽  
Zain Kassam ◽  
Chris J.J. Mulder ◽  
...  
Keyword(s):  
Celiac Disease ◽  
T Cell ◽  
Clostridium Difficile ◽  
Clostridium Difficile Infection ◽  
Cell Lymphoma ◽  
Fecal Microbiota ◽  
Disease Type ◽  
T Cell Lymphoma ◽  
Type Ii ◽  
Refractory Celiac Disease

Treatment of refractory celiac disease type II (RCD II) and preventing the development of an enteropathy associated T-cell lymphoma in these patients is still difficult. In this case report, we describe a patient with RCD II who received fecal microbiota transfer as treatment for a recurrent Clostridium difficile infection, and remarkably showed a full recovery of duodenal villi and disappearance of celiac symptoms. This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II. Abbreviations: CDI: Clostridium difficile infection; EATL : enteropathy associated T-cell lymphoma; FMT: fecal microbiota transfer; IEL: intraepithelial lymphocytes; RCD II: refractory celiac disease type II; TPN: total parenteral nutrition.

scholarly journals A242 SIGMOID PERFORATION: A RARE CASE OF REFRACTORY CELIAC DISEASE TYPE II

2018 ◽  
Vol 1 (suppl_2) ◽  
pp. 354-354
Author(s):  
R Chibbar ◽  
J Nostedt ◽  
D Mihalicz ◽  
R Mclean ◽  
J deschenes ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Rare Case ◽  
Disease Type ◽  
Type Ii ◽  
Refractory Celiac Disease ◽  
Sigmoid Perforation

scholarly journals Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy

2010 ◽  
Vol 46 (6) ◽  
pp. 840-846 ◽  
Author(s):  
G J Tack ◽  
M J Wondergem ◽  
A Al-Toma ◽  
W H M Verbeek ◽  
A Schmittel ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Disease Type ◽  
Type Ii ◽  
Refractory Celiac Disease

The Intracellular Intensity of CD3 on Aberrant Intraepithelial Lymphocytes Is a Prognostic Factor of the Progression to Overt Lymphoma in Refractory Celiac Disease Type II (Pre-Enteropathy-Associated T Cell Lymphoma)

2020 ◽  
Vol 38 (6) ◽  
pp. 490-499 ◽  
Author(s):  
Carlota García-Hoz ◽  
Laura Crespo ◽  
Natalia Lopez ◽  
Ana De Andrés ◽  
Raquel Ríos León ◽  
...  
Keyword(s):  
Celiac Disease ◽  
T Cell ◽  
Cell Lymphoma ◽  
Intraepithelial Lymphocytes ◽  
Disease Type ◽  
T Cell Lymphoma ◽  
Control Group ◽  
Type Ii ◽  
Refractory Celiac Disease ◽  
Single Center Study

<b><i>Background:</i></b> Refractory celiac disease type II (RCD-II) is a very rare yet severe complication of celiac disease (CD) with a 50% rate of progression to Enteropathy-associated T-cell lymphoma (EATL). Timely diagnosis and treatment of RCD-II is of the essence and requires the identification of a population of frequently clonal, phenotypically aberrant intraepithelial lymphocytes (IELs). Flow Cytometry of intestinal IELs is the recommended method to identify the aberrant surface CD3-negative (sCD3<sup>–</sup>) intracytoplasmic CD3-positive (icCD3ε<sup>+</sup>) IELs, and a proportion of &#x3e;20% is diagnostic of RCD-II. There is substantial heterogeneity in the clinical course of RCD-II, and insufficient information on prognostic factors. <b><i>Aim:</i></b> To establish flow cytometric predictors of the clinical evolution of RCD-II, to help guide treatment approaches. <b><i>Patients and Methods:</i></b> Retrospective single-center study of clinical and immunological features of 6 RCD-II patients and a control group, both identified from a 2,000-patient cohort over 16 years. IEL subset frequencies and the intensity of staining for surface (s) and intracytoplasmic (ic) CD3ε+ on IEL subsets were quantified and correlated with the clinical outcome. <b><i>Results:</i></b> Unexpectedly, the frequency of aberrant sCD3<sup>–</sup> icCD3ε<sup>+</sup> cells at diagnosis did not correlate with histological or clinical affection. However, a higher intensity of icCD3ε<sup>+</sup> staining in the aberrant IELs relative to expression on normal IELs correlated with monoclonality and with worse clinical outcomes. <b><i>Conclusion:</i></b> The ratio of icCD3ε<sup>+</sup> on aberrant IELs vs. normal IELs appears to be a useful indicator of prognosis at the time of diagnosis, and may represent a novel tool in the follow-up of RCD-II patients after therapy.

Sa1772 Ilc-Like Lymphomas in Refractory Celiac Disease Type II Respond to Multiple Common γ-Chain Cytokines and Are Sensitive to JAK-Inhibitors

2015 ◽  
Vol 148 (4) ◽  
pp. S-328
Author(s):  
Yvonne Kooy-Winkelaar ◽  
Frederike Schmitz ◽  
M. Luisa Mearin ◽  
Gerd Bouma ◽  
Chris J. Mulder ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Disease Type ◽  
Type Ii ◽  
Jak Inhibitors ◽  
Refractory Celiac Disease
Sign in / Sign up

Export Citation Format

Share Document